CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,106,536 | +43.5% | 37,207 | -13.1% | 0.00% | 0.0% |
| Q2 2023 | $771,183 | +51.4% | 42,796 | +34.9% | 0.00% | 0.0% |
| Q1 2023 | $509,424 | -6.2% | 31,720 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $543,181 | -11.1% | 29,682 | -4.5% | 0.00% | 0.0% |
| Q3 2022 | $611,000 | +19.6% | 31,066 | +13.2% | 0.00% | 0.0% |
| Q2 2022 | $511,000 | -6.6% | 27,436 | +10.1% | 0.00% | – |
| Q1 2022 | $547,000 | -5.2% | 24,930 | +22.7% | 0.00% | – |
| Q4 2021 | $577,000 | +89.8% | 20,317 | +41.3% | 0.00% | – |
| Q3 2021 | $304,000 | +13.0% | 14,382 | +0.6% | 0.00% | – |
| Q2 2021 | $269,000 | +68.1% | 14,290 | +36.2% | 0.00% | – |
| Q1 2021 | $160,000 | -38.7% | 10,492 | -43.2% | 0.00% | – |
| Q4 2020 | $261,000 | +23.7% | 18,470 | +53.2% | 0.00% | – |
| Q2 2020 | $211,000 | – | 12,057 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |